More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

During the COVID pandemic's height, for example, Pfizer was not only the co-developer of the widely distributed Comirnaty vaccine, it was also the entity behind the go-to drug therapy Paxlovid.

Fiera Capital Corp trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission ...

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

At the same time, the COVID-19 oral therapy Paxlovid and the commercially available Comirnaty vaccine remain a big recurring ...